PD-1 blockade in melanoma: A promising start, but a long way to go
A partir de données portant sur 655 patients atteints d'un mélanome de stade avancé ou métastatique et ayant été inclus dans un essai de phase 1b, cette étude évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du pembrolizumab
In this issue of JAMA, the report by Ribas and colleagues presents findings from a pooled analysis of 655 patients with advanced melanoma who received pembrolizumab in the KEYNOTE-001 trial, an open-label multicohort study. Of these 655 patients, 173 were included in the randomized trial previously reported by Robert et al, 135 were included in the nonrandomized cohort previously reported by Hamid et al, and 347 were not included in prior reports.
JAMA , éditorial, 2015